T1	Participants 922 1043	40 children enrolled, 39 completed the trial over a period of 18 months; 19 received risperidone, and 20 received placebo
T2	Participants 548 718	40 consecutive children with autism, whose ages ranged from 2 to 9 years, who were receiving either risperidone or placebo given orally at a dose of 1 mg/day for 6 months
